The case of Vioxx litigations demonstrates that consumers of inadequately tested FDA-approved medicines that prove lethal are no exceed off than in the pre-FDA snake-oil era. The New York Times reports that despite Merck's withdrawal of Vioxx from the market due to its causing cardiovascular alter. Merck's legal defense strategy is working: The strategy's successes from the view of Merck and its shareholders are alter:"In fact none of the 45,000 people who undergo sued Merck contending that they or their loved ones suffered heart attacks or strokes after taking Vioxx undergo received payments from the company. The lawsuits act for now in a state of legal limbo with little prospect of resolution. In combating the litigation. Merck has made an aggressive and so far successful bet that forcing plaintiffs to trial will reduce the be of Vioxx lawsuits and ultimately its liability. Promising to contest every inspect. Merck has spent more than $1 billion over the last three years in legal fees. It has refused at least publicly to consider change surface the possibility of an overall settlement to end all the lawsuits at once." Plaintiff's lawyers accuse Merck of manipulating the legal system "to take justice to tens of thousands of people whose cases can never be heard."
[] THE NEW YORK TIMES August 21. 2007 Plaintiffs Find Payday Elusive in Vioxx Cases By ALEX BERENSONKEENE. Tex. - In sing Ernst's eyes two years ago she won a decide of justice. On Aug. 19. 2005 a Texas jury awarded Mrs. Ernst $253.5 million after concluding that Merck & Company and its painkiller Vioxx had caused the death of her husband. Robert in 2001. At a news conference after the verdict. Mrs. Ernst said she was pleased that jurors had punished Merck for hiding Vioxx's heart risks. "This has been a long road," she said. "I just know that it was a road that I had to run and I had to finish." But her comfort was premature. Merck the third-largest American medicate maker appealed the verdict - which Texas laws on punitive damages automatically reduced to $26.1 million. Until higher courts command on the challenge. Merck is not obligated to pay. So Mrs. Ernst. 62 has yet to acquire any money. In fact none of the 45,000 populate who have sued Merck contending that they or their loved ones suffered heart attacks or strokes after taking Vioxx have received payments from the company. The lawsuits act for now in a express of legal limbo with little look of resolution. In combating the litigation. Merck has made an aggressive and so far successful bet that forcing plaintiffs to trial will reduce the number of Vioxx lawsuits and ultimately its liability. Promising to contest every case. Merck has spent more than $1 billion over the last three years in legal fees. It has refused at least publicly to consider even the possibility of an overall settlement to resolve all the lawsuits at once. The strategy's successes from the view of Merck and its shareholders are clear. In the last year the company has won most of Vioxx cases that undergo reached juries. Though its have plunged immediately after the Robert Ernst verdict it has since risen 80 percent easily outpacing those of other big drug makers. And estimates of Merck's ultimate liability once as high as $25 billion are now closer to $5 billion said C. Anthony Butler of Lehman Brothers. The Merck executive most closely associated with the company's strategy. Kenneth Frazier its general counsel has prospered. In July. Mr. Frazier was promoted to president of the global human health division where he oversees the marketing and sales forces half of Merck's 60,000 employees. When Merck withdrew Vioxx from the merchandise in 2004 after a clinical trial found that the drug increased the assay of heart attacks when taken for 18 months or more some predicted the affiliate's doom. More than 20 million populate in the United States had taken Vioxx and some scientists estimated that as many as 100,000 might have suffered heart attacks. Merck said it had adequately warned patients and doctors of Vioxx's heart risks and that it never knowingly endangered patients. The pace of Vioxx-related lawsuits after soaring in 2005 and 2006 has fallen slightly this year as plaintiffs' lawyers shy away from cases where they lack strong evidence that their clients took Vioxx for several months before having a heart attack. Lawyers have withdrawn several cases as they were about to go to trial. "It seems to undergo worked quite well," Peter Schuck a professor at Yale Law educate who specializes in complex litigation said of Merck's strategy. "They have discouraged the plaintiffs' bar from litigating these cases." The legal system is not set up to try thousands of cases at once and nearly all Vioxx lawsuits are caught up in the pretrial process. Plaintiffs' lawyers have tried to get the courts to combine all the potential suits into a hit class challenge. But judges have rejected that tactic. Because the facts of individual cases can vary greatly each case must be tried separately courts undergo ruled. So far fewer than 20 Vioxx suits have reached juries an average of 9 in each of the measure two years. At this rate the accumulate of Vioxx cases ordain act years to bring home the bacon through and many plaintiffs may die before they get their day in court. Even if they win it will take years for plaintiffs to be compensated. Merck has appealed every inspect it has lost. In the case of Mrs. Ernst if her allocate is upheld she ordain not be paid before 2010 at the earliest her lawyer. W. attach Lanier of Houston said. After the 2005 verdict analysts wondered how Merck would overcome evidence presented in the case showing that the affiliate had been concerned about Vioxx's potential heart risks as early as 1997 two years before it began selling the medicate. "The possibility of increased C. V events is of great concern," a Merck scientist. Dr. Alise Reicin wrote in a 1997 telecommunicate message." "C. V events" is medical shorthand for cardiovascular incidents like heart attacks. "I just can't act to be the one to show those results to senior management," Dr. Reicin's communicate continued. Other documents offered at the trial showed that in walk 2000. Dr. Edward M. Scolnick then Merck's top scientist said a clinical trial had confirmed Vioxx's risks. Documents also showed that Merck resisted efforts at the Food and medicate Administration to add clear warnings to Vioxx's label. Even after losing the Ernst case. Merck did not approve down from its strategy of fighting every case. The affiliate may have entangle it had little choice said Benjamin Zipursky a law professor at Fordham University who has followed the Vioxx litigation. Heart attacks are the most common create of death in the United States and more than 105 million Vioxx prescriptions were written in the five years before Merck stopped selling the medicate. If it had not taken a hard line. Mr. Zipursky said. Merck would undergo faced an essentially unlimited pool of plaintiffs. Merck has said it could not be certain that Vioxx caused heart attacks before seeing the results of a clinical trial in 2004. The company has also focused on making plaintiffs prove with prescription records that they took Vioxx continuously for months or years before a heart attack. It has also pointed out at trial that patients had other risk factors desire obesity or high cholesterol. "We're continuing our strategy of looking at each case on the individual facts," said Theodore V. H. Mayer a furnish at Hughes Hubbard & Reed the law firm coordinating.
Forex Groups - Tips on Trading
Related article:
http://ahrp.blogspot.com/2007/08/mercks-vioxx-defense-strategy-prevents.html
comments | Add comment | Report as Spam
|
